Rxsight Inc (RXST)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $223.06M
Last updated: Nov 17, 2026 at 11:05 AM ET
Rxsight Inc (RXST) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Rxsight reported EPS of -$0.39, above the -$0.42 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RXST's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
RXST Earnings Call
The latest RXST earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 22 quarters below that had an estimate, RXST beat 16 and missed 6. Revenue for the quarter ended Sep 30, 2026 was $24.59M, down 19.0% from $30.34M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.39 | -$0.42 | N/A | +7.14% | Beat | N/A | 5 | N/A | Nov 3, 2026 | $24.59M |
| Jun 30, 2026 | -$0.29 | -$0.37 | N/A | +21.62% | Beat | N/A | 5 | 1 up, 1 down | Aug 5, 2026 | $33.74M |
| Mar 31, 2026 | -$0.19 | -$0.15 | -$0.22 - -$0.12 | -26.67% | Miss | N/A | 5 | 1 up, 2 down | May 6, 2026 | $30.89M |
| Dec 31, 2025 | -$0.03 | -$0.34 | -$0.35 - -$0.11 | +91.12% | Beat | -200.0% | 4 | 1 up, 1 down | Feb 25, 2026 | $32.61M |
| Sep 30, 2025 | -$0.24 | -$0.34 | -$0.35 - -$0.05 | +29.41% | Beat | N/A | 5 | N/A | Nov 5, 2025 | $30.34M |
| Jun 30, 2025 | -$0.29 | -$0.28 | N/A | -3.57% | Miss | N/A | 6 | 0 up, 4 down | Aug 7, 2025 | $33.64M |
| Mar 31, 2025 | -$0.03 | -$0.08 | -$0.26 - $0.02 | +62.50% | Beat | N/A | 6 | 0 up, 2 down | May 7, 2025 | $37.90M |
| Dec 31, 2024 | $0.03 | -$0.17 | -$0.18 - $0.14 | +117.65% | Beat | N/A | 5 | 0 up, 1 down | Feb 25, 2025 | $40.21M |
| Sep 30, 2024 | -$0.16 | -$0.07 | N/A | -128.57% | Miss | N/A | 8 | 0 up, 0 down | Nov 7, 2024 | $35.31M |
| Jun 30, 2024 | -$0.16 | -$0.11 | N/A | -45.45% | Miss | N/A | 6 | 1 up, 0 down | Aug 5, 2024 | $34.89M |
| Mar 31, 2024 | -$0.12 | -$0.19 | -$0.32 - -$0.07 | +36.84% | Beat | N/A | 8 | 0 up, 0 down | May 6, 2024 | $29.51M |
| Dec 31, 2023 | -$0.26 | -$0.36 | -$0.41 - -$0.30 | +27.78% | Beat | N/A | 7 | 0 up, 0 down | Feb 28, 2024 | $28.58M |
| Sep 30, 2023 | -$0.19 | -$0.35 | N/A | +45.71% | Beat | N/A | 6 | 0 up, 0 down | Nov 9, 2023 | $22.20M |
| Jun 30, 2023 | -$0.28 | -$0.39 | N/A | +28.21% | Beat | N/A | 6 | 0 up, 1 down | Aug 7, 2023 | $20.81M |
| Mar 31, 2023 | -$0.31 | -$0.45 | -$0.59 - -$0.42 | +31.11% | Beat | N/A | 6 | 1 up, 0 down | May 9, 2023 | $17.49M |
| Dec 31, 2022 | -$0.56 | -$0.75 | -$0.80 - -$0.68 | +25.33% | Beat | N/A | 4 | 0 up, 1 down | Mar 6, 2023 | $16.09M |
| Sep 30, 2022 | -$0.61 | -$0.68 | -$0.75 - -$0.68 | +10.29% | Beat | N/A | 5 | 0 up, 0 down | Nov 7, 2022 | $12.62M |
| Jun 30, 2022 | -$0.61 | -$0.65 | N/A | +6.15% | Beat | N/A | N/A | 0 up, 0 down | Aug 8, 2022 | $11.36M |
| Mar 31, 2022 | -$0.64 | -$0.60 | -$0.68 - -$0.59 | -6.67% | Miss | N/A | 5 | 0 up, 0 down | May 5, 2022 | $8.94M |
| Dec 31, 2021 | -$0.58 | -$0.68 | -$0.93 - -$0.59 | +14.71% | Beat | N/A | 4 | 0 up, 0 down | Mar 8, 2022 | $8.43M |
| Sep 30, 2021 | -$0.68 | -$0.62 | -$0.67 - -$0.57 | -9.68% | Miss | N/A | 5 | N/A | Nov 10, 2021 | $5.79M |
| Jun 30, 2021 | -$0.51 | -$0.70 | -$0.76 - -$0.60 | +27.14% | Beat | N/A | 3 | 0 up, 0 down | Jul 30, 2021 | $4.90M |
| Mar 31, 2021 | -$0.36 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 2, 2021 | $3.48M |
| Dec 31, 2020 | -$1.70 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $4.91M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.59, after -$0.41 the year before. It was -$1.70 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.59 | N/A |
| Dec 31, 2024 | -$0.41 | N/A |
| Dec 31, 2023 | -$1.04 | N/A |
| Dec 31, 2022 | -$2.42 | N/A |
| Dec 31, 2021 | -$2.13 | N/A |
| Dec 31, 2020 | -$1.70 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,500 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,517 | 13 | |
| 2026Q2 | Jun 30, 2026 | 5,550 | 10 | |
| 2026Q1 | Mar 31, 2026 | 4,047 | 12 | |
| 2025Q4 | Dec 31, 2025 | 4,979 | 12 | |
| 2025Q3 | Sep 30, 2025 | 5,350 | 12 | |
| 2025Q2 | Jun 30, 2025 | 3,271 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,199 | 10 | |
| 2024Q4 | Dec 31, 2024 | 5,576 | 11 |
2026Q3 Earnings Call
Opening remarks
Oliver Moravcevic VP of Investor Relations Thank you, operator. With me on the call today are RxSight President and Chief Executive Officer, Aziz Mottiwala, and Chief Financial Officer, Mark Wilterding. Earlier today, RxSight released financial results for the three months ended September 30, 2026. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that comments and responses to questions during today's call reflect management's views as of today and will include forward-looking and opinion statements, including predictions, estimates, plans, and expectations. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued today and in our filings with the Securities and Exchange Commission, or SEC. Our SEC filings can be found on our website or the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements, and we disclaim any obligation to update or revise these forward-looking statements, except as may be required by law. We will also discuss certain non-GAAP financial measures. Disclosures regarding non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that this conference call will be available for audio replay on our Investor Relations website. With that, I will turn the call over to Aziz.
Aziz Mottiwala President and CEO Thank you, Oliver, and good afternoon, everyone. I've been at RxSight for just over 90 days, and I want to start by saying how impressed I am with the team and what we've accomplished in such a short time. What has stood out to me most is the passion our people have for our technology, their commitment to patients, and their determination to position the company for long-term success. We have a strong foundation of talent across the organization, and I'm equally excited about the new leadership and capabilities we've added over the past several months. During this time, I've also prioritized being in the field and meeting with our key physician customers. Their feedback has been consistent and reinforces my conviction in RxSight's technology. They strongly believe in the benefits of the Light Adjustable Lens and the differentiated visual outcomes LAL delivers. These conversations have also provided valuable insights into how physicians are using our technology and where we have opportunities to better support their practices and drive broader adoption. When we spoke last quarter, I outlined my three initial focus areas: develop a deeper understanding of the business, identify the underlying challenges and opportunities, and determine where we could have the greatest impact.
Frequently Asked Questions About RXST
Did RXST beat earnings estimates last quarter?
Yes. Rxsight reported EPS of -$0.39 for the quarter ended Sep 30, 2026, above the -$0.42 estimate, a 7.14% surprise.
What EPS do analysts expect from RXST next quarter?
The consensus EPS estimate for Rxsight for the quarter ending Dec 31, 2026 is $0.11 from 12 analysts, with estimates from -$0.31 to $0.26.
How often does RXST beat earnings estimates?
Rxsight beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +37.40%.
RXST pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors